Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 142 participants.
Also called NCT06959784
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 142 participants
- Registry
-
NCT06959784
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT06959784. Randomized; no masking; primary purpose treatment. Start 2024-01-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
- Condition
- Diabetes Mellitus
- Condition
- Cardiovascular Diseases
- Condition
- Cerebrovascular Disease
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- Metformin
- Lead sponsor
- China-Japan Friendship Hospital
Record details
- Record id
cardio:ct-nct06959784- Content hash
568cc148a5636eb8b53dd4ce1bcdef9146b721608f1bb6abbea079c9c0aa69e6